Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Zeynep Eroglu MD

Zeynep Eroglu MD

Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma. 

Recent Contributions to PracticeUpdate:

  1. IFN-γ Signature Enables the Selection of Neoadjuvant Treatment in Patients With Stage III Melanoma
  2. Neoadjuvant–Adjuvant vs Adjuvant-Only Pembrolizumab for Advanced Melanoma
  3. Combining Melphalan Percutaneous Hepatic Perfusion With Ipilimumab Plus Nivolumab for Advanced Uveal Melanoma
  4. Tumor-Infiltrating Lymphocyte Therapy vs Ipilimumab for Advanced Melanoma
  5. Overall Survival With First-Line Atezolizumab Plus Vemurafenib and Cobimetinib in BRAFV600-Positive Advanced Melanoma
  6. Trends in Health Care Resource Utilization and Costs of Systemic Therapies for Metastatic Melanoma
  7. 2022 Top Story in Advanced Melanoma: RELATIVITY-047— Relatlimab–Nivolumab in Untreated Advanced Melanoma
  8. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Patients With Melanoma Receiving Adjuvant Immune Checkpoint Blockade
  9. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
  10. Outcomes of Adjuvant Anti–PD-1 Therapy in Patients With SLN-Positive Melanoma Who Did Not Undergo Completion Lymph Node Dissection

Recently Updated